GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » 12-1 Month Momentum %

HCWB (HCW Biologics) 12-1 Month Momentum % : -81.37% (As of Apr. 23, 2025)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-23), HCW Biologics's 12-1 Month Momentum % is -81.37%.

The industry rank for HCW Biologics's 12-1 Month Momentum % or its related term are showing as below:

HCWB's 12-1 Month Momentum % is ranked worse than
90.3% of 1443 companies
in the Biotechnology industry
Industry Median: -18.64 vs HCWB: -81.37

Competitive Comparison of HCW Biologics's 12-1 Month Momentum %

For the Biotechnology subindustry, HCW Biologics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's 12-1 Month Momentum % falls into.


;
;

HCW Biologics  (NAS:HCWB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics  (NAS:HCWB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


HCW Biologics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of HCW Biologics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057